Skip to main content

Redx Pharma hails new drug candidate for leukaemia and arthritis

Redx Pharma hails new drug candidate for leukaemia and arthritis

Seneca EIS portfolio company Redx Pharma has identified another potential blockbuster from its pipeline of drug candidates. Its oncology arm has found a would-be treatment for leukaemia and other blood cancers, and auto-immune diseases, such as lupus.

It is the second drug to come through the development system. Redx has 13 drug programmes in its pipeline.

Chief executive (CEO) Neil Murray said: “This drug candidate has the potential to demonstrate efficacy without the highly unpleasant side effects that many existing treatments display. We have a number of other promising candidates in the pipeline and we’re looking forward to seeing these progress into development in the near future.”

See the article in full at proactiveinvestors.co.uk